Literature DB >> 15452240

Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Kimberly Ritola1, Christopher D Pilcher, Susan A Fiscus, Noah G Hoffman, Julie A E Nelson, Kathryn M Kitrinos, Charles B Hicks, Joseph J Eron, Ronald Swanstrom.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) exists as a complex population of multiple genotypic variants in persons with chronic infection. However, acute HIV-1 infection via sexual transmission is a low-probability event in which there is thought to be low genetic complexity in the initial inoculum. In order to assess the viral complexity present during primary HIV-1 infection, the V1/V2 and V3 variable regions of the env gene were examined by using a heteroduplex tracking assay (HTA) capable of resolving these genotypic variants. Blood plasma samples from 26 primary HIV-1-infected subjects were analyzed for their level of diversity. Half of the subjects had more than one V1/V2 viral variant during primary infection, indicating the frequent transmission of multiple variants. This observation is inconsistent with the idea of infrequent transmission based on a small transmitting inoculum of cell-free virus. In chronically infected subjects, the complexity of the viral populations was even greater in both the V1/V2 and the V3 regions than in acutely infected subjects, indicating that in spite of the presence of multiple variants in acute infection, the virus does pass through a genetic bottleneck during transmission. We also examined how well the infecting virus penetrated different anatomical compartments by using the HTA. Viral variants detected in blood plasma were compared to those detected in seminal plasma and/or cerebral spinal fluid of six individuals. The virus in each of these compartments was to a large extent identical to virus in blood plasma, a finding consistent with rapid penetration of the infecting variant(s). The low-probability transmission of multiple variants could be the result of transient periods of hyperinfectiousness or hypersusceptibility. Alternatively, the inefficient transfer of a multiply infected cell could account for both the low probability of transmission and the transfer of multiple variants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452240      PMCID: PMC521858          DOI: 10.1128/JVI.78.20.11208-11218.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

2.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

3.  Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII.

Authors:  C A Ludlam; J Tucker; C M Steel; R S Tedder; R Cheingsong-Popov; R A Weiss; D B McClelland; I Philp; R J Prescott
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

4.  Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution.

Authors:  T F Wolfs; G Zwart; M Bakker; M Valk; C L Kuiken; J Goudsmit
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

5.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

6.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

7.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Authors:  Brian J Rybarczyk; David Montefiori; Philip R Johnson; Ande West; Robert E Johnston; Ronald Swanstrom
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Genomic human immunodeficiency virus type 1 RNA variation in mother and child following intra-uterine virus transmission.

Authors:  G A Mulder-Kampinga; C Kuiken; J Dekker; H J Scherpbier; K Boer; J Goudsmit
Journal:  J Gen Virol       Date:  1993-09       Impact factor: 3.891

10.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

View more
  69 in total

Review 1.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus.

Authors:  Rick B Meeker; D C Bragg; Winona Poulton; Lola Hudson
Journal:  Cell Tissue Res       Date:  2012-01-27       Impact factor: 5.249

3.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Authors:  Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  Bursts of nonsynonymous substitutions in HIV-1 evolution reveal instances of positive selection at conservative protein sites.

Authors:  Georgii A Bazykin; Jonathan Dushoff; Simon A Levin; Alexey S Kondrashov
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

5.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

6.  Single-chain Fv-based anti-HIV proteins: potential and limitations.

Authors:  Anthony P West; Rachel P Galimidi; Priyanthi N P Gnanapragasam; Pamela J Bjorkman
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 7.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

8.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

9.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.